Stenotrophomonas maltophilia

Binks PR, S Nicklin, NC Bruce (1995) Degradation of hexahydro-l,3,5-trinitro-l,3,5-triazine (RDX) by Stenotrophomonas maltophilia PBl.Appl Environ Microbiol 61 1318-1322. 

The biodegradation of pyrene, chrysene, fluoranthene, benz[a]anthracene, dibenz[a,/t] anthracene, benzo[a]pyrene, and coronene by Stenotrophomonas maltophilia has been studied in the presence of a range of synthetic surfactants (Boonchan et al. 1998). Nonneutral surfactants were toxic, biodegradation was also inhibited by the neutral Igepal CA-630, and the positive enhancement of removal of substrates was generally low—in the range of 10%. 

Boonchan S, ML Britz, GA Stanley (1998) Surfactant-enhanced biodegradation of high molecular weight polycyclic aromatic hydrocarbons by Stenotrophomonas maltophilia. Biotechnol Bioeng 59 480-494. 

Resting cells of bacterium Stenotrophomonas maltophilia CGMCC 1.1788 catalyze the stereoselective hydroxylation at position C12 of imidacloprid (IMl) in the imidazolidine ring to form (R)-5-hydroxy IML Under acidic conditions, 5-hydroxy IMI is converted into olefin IMl (Figure 12.2), which exhibits about 19 times more insecticidal efficacy than IMI against horsebean aphid imago. 

Stenotrophomonas maltophilia. Vibrio cholerae, Citrobacter freundii, Pseudomonas Probes hybridization ... 

Stenotrophomonas maltophilia (formerly Xanthomonas maltophilia) TMP-SMZ1 Minocycline, ticarcillin-clavulanate, tigecycline, ceftazidime, quinolone3... 

Clinafloxacin, moxifloxacin, sparfloxacin, and trovaflox-acin were significantly more active in vitro than ciprofloxacin and levofloxacin against Stenotrophomonas maltophilia, a microorganism with inherent resistance to many antibiotics new-generation quinolones may become very useful in the treatment of certain severe or life-threatening infectious conditions due to this bacterium (113). 

Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000 45(3) 363-5. 

Intermittent administration of inhaled tobramycin has been recommended in patients with cystic fibrosis, as it improves pulmonary function, reduces the density of P. aeruginosa in sputum, and reduces the risk of hospitalization. The proportion of patients with isolates of P. aeruginosa with higher minimal inhibitory concentrations of tobramycin may increase (39). Treatment with inhaled tobramycin does not increase isolation of Burkholderia cepacia, Stenotrophomonas maltophilia, or Alcaligenes xylosoxidans however, isolation of Candida albicans and Aspergillus species may increase (40). 

Trimethoprim is fairly active against a variety of Grampositive cocci and Gram-negative rods. Established indications for co-trimoxazole are infections of the sinuses, ears, lungs, and urinary tract, and infections due to Salmonella, Nocardia, Brucella, Stenotrophomonas maltophilia, Pneumocystis proved, and Toxoplasma (1,6). Co-trimoxazole is also used in the treatment of Wegener s granulomatosis, for prevention of spontaneous bacterial peritonitis, and in patients with advanced HIV infection for the prophylaxis of opportunistic infections (1,6). 

In addition to the impact on P. aeruginosa MICs, the use of inhaled tobramycin is also associated with an increased rate of isolation of fungus in the sputum, including Candida albicans and Aspergillus species [32]. The increased presence of these fungi did not appear to be associated with deterioration in clinical status. The chronic use of inhaled tobramycin has not been associated with an increased risk of colonization or infection with other bacteria, including Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans. 

Zhang, L Li, X.Z. and Poole, K. (2001) Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. The Journal of Antimicrobial Chemotherapy, 48 (4), 549-552. 

Dungan, R. S., Yates, S. R. and Frankenberger, W. T., Jr. (2003). Transformations of selenate and selenite by Stenotrophomonas maltophilia isolated from a seleniferous agricultural drainage pond sediment. Environ. Microbiol. 5, 287-295. 

Sanschagrin, F., Levesque, R. C. (2005). A specific peptide inhibitor of the class B metallo-beta-lactamase L-1 from Stenotrophomonas maltophilia identified using phage display. J. Antimicrob. Chemother., 55, 252-255. 

---